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ard ratio 0.66, range 0.43–1.03). An interaction model illus-
trated that  KRAS p.G12C was associated with unfavorable 
outcome when treated with oxaliplatin plus cetuximab.  Con-
clusion: The present analysis suggests that  KRAS codon 12 
mutation may not represent a homogeneous entity in mCRC 
when treated with cetuximab-based first-line therapy. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Kirsten-ras  (KRAS) is a proto-oncogene encoding a 
small G protein. The KRAS protein is located at the in-
ner cell membrane and has guanosine triphosphatase
(GTPase) activity. Extracellular binding of ligands to 
transmembrane receptors like the epidermal growth fac-
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 Abstract 
 Purpose: This study investigated the impact of specific mu-
tations in codon 12 of the Kirsten-ras (KRAS) gene on treat-
ment efficacy in patients with metastatic colorectal cancer 
(mCRC).  Patients: Overall, 119 patients bearing a  KRAS muta-
tion in codon 12 were evaluated. All patients received cetu-
ximab-based first-line chemotherapy within the Central Eu-
ropean Cooperative Oncology Group (CECOG), AIO KRK-
0104 or AIO KRK-0306 trials.  Results: Patients with  KRAS 
codon 12 mutant mCRC showed a broad range of outcome 
when treated with cetuximab-based first-line regimens. Pa-
tients with tumors bearing a  KRAS p.G12D mutation showed 
a strong trend to a more favorable outcome compared to 
other mutations (overall survival 23.3 vs. 14–18 months; haz-
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tor receptor (EGFR) causes activation of the downstream 
signal transduction cascade to the nucleus. In the first 
step, the intracellular tyrosine kinase domain of the 
EGFR is phosphorylated which in turn induces a tran-
sient activation of the RAS protein. While in its inactive 
state, RAS is bound to guanosine diphosphate (GDP), ac-
tivation occurs by the conversion of GDP to GTP  [1, 2] .
 Mutations of the  KRAS gene are described to occur in 
approximately 40% of metastatic colorectal cancers. The 
mutations of  KRAS are point mutations and are mostly 
( 1 90%) detected in codon 12 (approx. 80%) and codon 13 
(approx. 20%) and are far less frequent in other codons 
like codon 61  [2–6] . In some studies, different types of 
 KRAS mutations, mostly in codon 13, were reported to be 
associated with a more aggressive biology concerning the 
risk of relapse after initial surgery was performed for 
colorectal cancer  [7, 8] . For metastatic colorectal cancer 
(mCRC), mutations in the  KRAS proto-oncogene have 
been identified as determinants of poor response to anti-
EGFR antibodies such as cetuximab and panitumumab 
leading to an exclusion of affected patients from anti-EG-
FR therapy  [9–13] . However, several recent studies did 
not identify wild-type KRAS alone to be a strong predic-
tor of response to anti-EGFR antibodies  [14–16] .
 In patients with  KRAS mutated tumors, the combina-
tion of FOLFOX plus anti-EGFR-directed antibodies 
showed trends to be associated with shorter overall sur-
vival (OS) when compared to FOLFOX alone in the 
PRIME study (15.5 vs. 19.3 months; p = 0.068) and in the 
smaller OPUS study (13.4 vs. 17.5 months; p = 0.2)  [11, 17] .
 Disappointing outcomes in patients undergoing treat-
ment with anti-EGFR antibodies and chemotherapy were 
mostly observed in studies using an oxaliplatin-based 
chemotherapy backbone, while this was not the case in 
studies using irinotecan-based chemotherapy backbones 
 [10, 18] . Therefore, it has been hypothesized that an un-
known mechanism of inhibitory interaction may exist for 
the combined use of anti-EGFR agents and oxaliplatin in 
patients with  KRAS mutant mCRC.
 The concept of  KRA S mutant tumors as a uniform en-
tity generally resistant to anti-EGFR antibodies was first 
questioned by de Roock and coworkers  [19] . In a recent 
report based on preclinical and clinical investigations, 
this group indicated that  KRAS p.G13D mutant mCRC 
compared to other  KRAS mutant tumors is associated 
with unfavorable outcome receiving best supportive care, 
but with a longer OS and progression-free survival (PFS) 
when treated with cetuximab.
 These findings are further supported by studies inves-
tigating the role of  KRAS mutations in the risk of relapse 
and death after primary resection of colorectal cancer. A 
decade ago,  KRAS mutation in codon 13 was identified as 
a risk factor of poor outcome  [7, 8, 20] . Other authors de-
scribed codon 12 mutation (p.G12V) as a marker of a 
highly aggressive disease  [8, 21] .
 In the present analysis, we investigate patients with 
mCRC exclusively characterized by a mutation in  KRAS 
codon 12. The study aims to analyze the question wheth-
er subtypes of  KRAS  codon 12 mutation have an impact 
on treatment outcome.
 Methods 
 KRAS Mutation Detection 
 All tumor samples were evaluated using validated methods of 
high sensitivity for KRAS diagnostics  [22, 23] . In terms of the AIO 
KRK-0104 and the AIO KRK-0306 trial,  KRAS  testing was per-
formed in a German reference laboratory for  KRAS  analysis (De-
partment of Pathology, University of Munich, Munich, Germa-
ny). Detection of mutations in codons 12 and 13 of the  KRAS pro-
to-oncogene was performed by pyrosequencing using Qiagen’s 
PyroMark Gold kits together with a Q24 pyrosequencer device 
 [5] . This procedure resulted in a specificity of 0.98 and a sensitiv-
ity of 0.99 for the detection of mutations in the  KRAS proto-on-
cogene  [5, 15, 18, 24] . The tumor samples belonging to the Central 
European Cooperative Oncology Group (CECOG) trial were ret-
rospectively tested for  KRAS by an allele-specific real-time poly-
merase chain reaction assay which demonstrated comparable 
precision in  KRAS testing (DxS Ltd., Manchester, UK)  [22, 23, 25] .
 Treatment Schedules 
 The AIO KRK-0104 study was designed as an open-label, ran-
domized phase II study as previously reported by Moosmann et 
al.  [15] and Modest et al.  [18] . It was conducted at 35 centers in 
Germany. In both study arms, cetuximab was given at an initial 
dose of 400 mg/m 2 as a 120-min infusion, followed by weekly in-
fusions of 250 mg/m 2 over 60 min. Patients in arm A received 
chemotherapy with CAPIRI (i.e. oral capecitabine 800 mg/m 2 
twice daily on days 1–14, followed by a 1-week rest period plus 
irinotecan 200 mg/m 2 as a 30-min intravenous infusion on day 1). 
In patients  1 65 years, doses were further reduced by 20%. Patients 
in arm B received chemotherapy with CAPOX (i.e. capecitabine 
1,000 mg/m 2 twice daily on days 1–14, followed by a 1-week rest 
period plus oxaliplatin 130 mg/m 2 as a 120-min intravenous infu-
sion on day 1). Treatment cycles were repeated every 3 weeks until 
disease progression or unacceptable toxicity  [15] .
 The ongoing AIO KRK-0306 study was designed as a random-
ized study and is presently conducted at 177 centers in Germany 
and Austria. This trial compares FOLFIRI plus cetuximab to 
FOLFIRI plus bevacizumab. Following an amendment, the study 
was closed for patients with  KRAS mutant mCRC in 2009. There-
fore, only patients with  KRAS mutated mCRC could be analyzed 
in the present analysis. As described before, only patients includ-
ed in the cetuximab arm were evaluated. FOLFIRI was applied as 
previously reported by Tournigand and coworkers  [26] . Irinote-
can (180 mg/m 2 ) was given as a 60-min infusion followed by fo-
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linic acid (400 mg/m 2 ), as a 120-min infusion and by an intrave-
nous bolus of 5-fluorouracil (5-FU; 400 mg/m 2 ) and 5-FU (2,400 
mg/m 2 ) applied as a 46-hour continuous infusion. The regimen 
was repeated every 2 weeks. Cetuximab was given at an initial 
dose of 400 mg/m 2 as a 120-min infusion, followed by weekly in-
fusions of 250 mg/m 2 over 60 min. Treatment was performed un-
til disease progression or unacceptable toxicity  [24] .
 The CECOG study was a two-arm randomized multicenter, 
open-label, parallel-group phase II study involving 28 participat-
ing centers across 13 countries (CECOG/CORE1.2.001). Eligible 
patients were centrally randomized 1: 1, using a minimization 
technique, stratifying patients according to study site, the number 
of organs involved and prior neoadjuvant/adjuvant therapy. Pa-
tients received cetuximab (400 mg/m 2 initial infusion on day 1, 
then 250 mg/m 2 weekly) and were then placed either in arm A or 
arm B: arm A, oxaliplatin (100 mg/m 2 on day 1) with FA [400 mg/
m 2 (racemic) or 200 mg/m 2 (L-form)] plus 5-FU (400 mg/m 2 bolus 
plus 2,400 mg/m 2 as a 46-hour continuous infusion) every 2 
weeks (FOLFOX6); arm B, irinotecan (180 mg/m 2 ) with the 5-FU/
FA regimen described (FOLFIRI)  [25] .
 Patients 
 The present analysis investigated 119 mCRC patients with a 
confirmed  KRAS mutation in codon 12 that received cetuximab-
based first-line therapy for mCRC. All patients were treated with-
in the AIO KRK-0104 (NCT00254137; 41 patients), the AIO KRK-
0306 (NCT00433927; 39 patients) or the CECOG trial (39 pa-
tients). A total of 62 patients received FOLFIRI, while 16 patients 
were treated with FOLFOX. Further 27 patients received CAPIRI 
and 14 patients CAPOX. The protocols of the clinical trials were 
approved by an independent ethics committee and governmental 
authorities. The trials were conducted in accordance with the 
Declaration of Helsinki (1996). All patients provided written and 
oral informed consent to be treated within the clinical trials.
 Endpoints 
 The present investigation was performed as an exploratory 
analysis. Radiological tumor response (complete remission, par-
tial remission, stable disease, progressive disease) was assessed 
according to RECIST criteria. Response evaluation was per-
formed at 6- to 8-week intervals. PFS was defined as the interval 
between randomization and first documentation of progression 
or death; OS was calculated as the time between randomization 
and death due to any reason. Patients alive were censored at the 
last time point of patient contact.
 Statistical Analysis 
 Data were summarized by adequate measures of location and 
variation for continuous variables and by proportions for discrete 
variables. Adequate tests for discrete data (  2-test) were used. 
Survival data were described by using the Kaplan-Meier estima-
tor. Differences in survival between the groups were tested by Cox 
regressions. Differences in OS and PFS were modelled using Cox 
proportional hazards regression where a treatment-covariate in-
teraction (irinotecan vs. oxaliplatin and codon 12 mutation sub-
type) was included. The resulting hazard ratios were tested by the 
Wald test. All statistical tests were performed two-sided, and a p 
value  ! 0.05 was considered statistically significant. All statistical 
analyses were performed using R (version 2.13.2) and IBM SPSS 
(version 19).
 Results 
 Study Population 
 This exploratory analysis includes 119 patients who re-
ceived first-line treatment for mCRC. Characteristics of 
the patients analyzed in this study do not indicate sig-
nificant differences regarding age, sex, ECOG status or 
primary disease sites when compared between the differ-
ent subgroups. The frequencies of  KRAS codon 12 muta-
tions within our study population were 44 p.G12D (37%), 
36 p.G12V (30%), 14 p.G12A (12%), 13 p.G12C (11%), 8 
p.G12S (7%) and 4 p.G12R (3%;  table 1 ).
 Impact of Codon 12 Subgroups on Parameters of 
Treatment Efficacy 
 Patients with  KRAS codon 12 mutated tumors showed 
significantly different response rates depending on the 
single mutation. Mutations in position 35 (p.G12D,
p.G12A, p.G12V) showed response rates of at least 40%, 
while mutations in position 34 (p.G12C, p.G12S, p.G12R) 
were associated with lower response rates of  ! 20%. Cor-
respondingly, PFS reached durations from 4.9 (p.G12C) 
to 9.8 months (p.G12A;  table 2 ).
 Median OS observed in this pooled analysis revealed 
marked differences between the single mutations. While 
patients with  KRAS p.G12D mutant mCRC showed an OS 
of 23.3 months, survival observed in patients with tumors 
bearing other  KRAS codon 12 mutations was generally 
shorter, reaching 14–18 months ( table 2 ;  figure 1 ).
 Interaction Tests: PFS and OS 
 PFS was illustrated by an interaction model including 
irinotecan versus oxaliplatin and the  KRAS mutation as 
possible parameters. If all  KRAS mutations were taken 
into account and p.G12D was defined as the ‘reference 
mutation’, a significant negative interaction (p = 0.03) was 
found in patients with  KRAS p.G12C mutant tumors who 
were treated with cetuximab- and oxaliplatin-containing 
regimens. This interaction test modeling OS instead of 
PFS again illustrated the negative interaction in patients 
with  KRAS p.G12C mutant tumors undergoing cetu-
ximab plus oxaliplatin-based first-line therapy (p = 0.002; 
 table 3 ).
 Discussion 
 Mutations of the  KRAS gene are observed in approxi-
mately 40% of sporadic colorectal cancers  [3, 6] . Gener-
ally, metastatic colorectal tumors are tested only for mu-
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tations in codons 12 and 13 of the  KRAS gene since the 
other possible mutations are less frequent. Codons 12 and 
13 of the  KRAS gene code for two adjacent glycine resi-
dues located in the proximity of the catalytic site of the 
RAS protein. The  KRAS mutations in codon 12 occur as 
point mutations in position 34 [c.34G ] A (p.G12S), 
c.34G ] C (p.G12R) and c.34G ] T (p.G12C)] or in posi-
tion 35 [c.35G ] A (p.G12D), c.35G ] C (p.G12A) and 
c.35G ] T (p.G12V)]. These mutations lead to a base ex-
change which in turn codes for different amino acids at 
the catalytic site of the resulting  KRAS protein. Although, 
the intrinsic level of KRAS-GTPase activity may be vari-
ably affected, the described clinical impact of the specific 
mutation is not consistent between different studies and 
tumor stages [19, 27, 28].
 Several studies performed in chemotherapy-refracto-
ry mCRC patients have indicated that anti-EGFR agents 
are not effective when tumors bear  KRAS mutations  [29–
33] . Subsequently, also in first-line studies, no benefit of 
anti-EGFR treatment was observed in patients with  KRAS 
mutant tumors  [10, 11, 17] . Therefore,  KRAS mutant 
mCRCs were generally regarded as resistant to anti-EG-
FR treatment. This assumption was maintained until re-
cently, when a study performed in pretreated patients 
demonstrated that also tumors with a c.38G ] A (p.G13D) 
mutation in codon 13 responded to treatment with cetu-
ximab  [19] .
 Our pooled analysis focused on  KRAS codon 12 muta-
tions and was designed to perform a comparative sub-
group analysis of the observed mutations.
 In our study, outcome parameters of patients with tu-
mors bearing a p.G12D mutation were generally more fa-
vorable compared to other mutations. A median OS of 
23.3 months observed for this subgroup compares well to 
the survival of patients with  KRAS wild-type tumors, as 
shown in various other trials  [10, 11, 17] . It might be im-
portant to note that the majority of patients with  KRAS 
p.G12D mutant mCRC in our pooled analysis were treat-
ed with cetuximab plus irinotecan-based chemotherapy. 
By contrast, no prognostic impact of p.G12D mutation 
compared to other  KRAS mutations in patients with 
mCRC receiving first-line treatment with FOLFOX plus 
Table 1. P atient characteristics according to KRAS mutation
Characteristics p.G12D p.G12V p.G12A p.G12C p.G12S p.G12R p value
Patients 44 36 14 13 8 4
Age, years
Median 63 63.5 62 67 66 62.5
Range 39–78 40–76 38–71 49–81 47–72 58–70
Sex, % 0.71
Female 36 28 36 38 12 50
Male 64 72 64 62 88 50
ECOG status, % 0.30
0 45 56 43 31 38 75
1 55 44 57 62 63 25
2 0 0 0 7 0 0
Primary tumor site, % 0.43
Colon 68 56 50 62 75 25
Rectum 32 44 50 38 25 75
Disease site, %
Liver 79 89 71 85 88 25 0.06
Lung 36 28 50 46 38 100 0.05
Peritoneum 14 11 8 0 0 0 0.55
Other 40 28 29 31 25 25 0.94
Subsets 0.20 
FOLFIRI 26 16 7 5 5 3
FOLFOX 3 9 1 0 2 1
CAPIRI 10 8 5 4 0 0
CAPOX 5 3 1 4 1 0
P ercentages are based on non-missing data. The 2 test was used for p values.
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panitumumab/placebo was described by a recent report 
 [34] . Taken together, these observations may point to a 
heterogeneous sensitivity of  KRAS codon 12 mutant tu-
mors to the combined use of chemotherapy plus anti-
EGFR antibody or to a prognostic impact of the mutation 
position. Our pooled analysis might be biased by the fact 
that the majority of patients received irinotecan-based 
regimens.
 The PRIME trial, comparing FOLFOX to FOLFOX 
plus panitumumab, demonstrated that patients with 
 KRAS mutant tumors have a better outcome when treat-
ed with FOLFOX alone compared to FOLFOX plus pani-
tumumab. This difference was nearly significant  [17] . A 
similar effect was observed in the OPUS trial (FOLFOX 
vs. FOLFOX plus cetuximab), although no statistical sig-
nificance was reached either  [11] . However, the CRYSTAL 
trial, using irinotecan-based chemotherapy, did not de-
scribe any differences in terms of OS in patients with 
 KRAS mutant tumors when cetuximab was added to 
FOLFIRI  [10] . Therefore, interactions between some 
 KRAS mutations and oxaliplatin might be suspected to 
cause negative effects in patients with mCRC. In our da-
taset, an interaction model in which p.G12D was used as 
the ‘reference mutation’ demonstrated that p.G12C muta-
tion correlates with poor outcome when treated with ox-
aliplatin-based first-line treatment. This finding might 
be supported by the translational analysis of the PRIME 
trial, which describes  KRAS p.G12C mutations to corre-
late with a poor prognostic impact on PFS and OS (OS not 
significant) when treated with FOLFOX alone compared 
to other  KRAS mutations  [34] .
 Due to the limited number of patients involved in the 
oxaliplatin-treated subgroup, conclusions must be drawn 
very carefully. However, our observations suggest that 
the combination of anti-EGFR-directed agents with spe-
cific chemotherapeutics may be an important determi-
nant of outcome with different effects in the respective 
mutation subgroup. Based on the present data, it could be 
hypothesized that the poor outcome of patients with 
Table 2. T reatment efficacy by KRAS codon 12 mutation in pa-
tients with mCRC undergoing cetuximab-based first-line treat-
ment
Mutation 
position
Mutation n ORR
%
PFS, months OS, months
Codon 
12–35
p.G12D 44 46 7.5 (6.8–8.2) 23.3 (17.8–28.8)
p.G12V 36 44 6.2 (3.2–9.2) 18.4 (13.9–22.9)
p.G12A 14 42 9.8 (5.3–14.3) 17.9 (12.6–23.1)
Codon 
12–34
p.G12C 13 17 4.9 (3.7–6.2) 14.3 (6.7–21.9)
p.G12S 8 13 8.3 (1.4–15.2) 15.2 (6.4–24.0)
p.G12R 4 0 5.3 (3.1–7.6) 15.5 (11.0–20.0)
p value 0.12
P ercentages are based on non-missing data. Figures in paren-
theses are 95% confidence intervals. ORR = Overall response rate. 
Table 3. I nteraction model with p.G12D as reference mutation
Mutation/treatment Hazard ratio 95% CI p value
PFS
Oxaliplatin 0.9 0.33–2.19 0.8
p.G12C 0.92 0.42–2.00 0.83
p.G12A 0.89 0.43–1.87 0.76
p.G12V 0.86 0.49–1.49 0.58
Oxaliplatin/p.G12C 5.35 1.21–23.70 0.03
Oxaliplatin/p.G12A 1.62 0.28–9.30 0.59
Oxaliplatin/p.G12V 1.81 0.59–5.52 0.30
OS
Oxaliplatin 0.81 0.30–2.17 0.68
p.G12C 1.41 0.60–3.30 0.43
p.G12A 1.71 0.81–3.58 0.16
p.G12V 1.23 0.67–2.26 0.50
Oxaliplatin/p.G12C 13.37 2.63–68.1 0.002
Oxaliplatin/p.G12A 1.75 0.18–17.7 0.63
Oxaliplatin/p.G12V 1.65 0.48–5.68 0.43
C ox proportional hazards regression/treatment covariate in-
teraction. p.G12S and p.G12R were not included due to limited 
sample size. p values by the Wald test.
0 0.5 1.0 1.5 2.0 2.5
Favors other mutantsFavors indicated
mutant
3.0 3.5
G12S
G12C
G12A
G12V
G12D
 Fig. 1. Prognostic impact of  KRAS subgroups on OS in patients 
receiving cetuximab-based first-line therapy. G12R was not as-
sessed due to limited sample size. Hazard ratios by Cox regres-
sions. 
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 KRAS codon 12–34 mutated tumors, especially those 
with p.G12C mutation, may be an important factor deter-
mining the disappointing survival of  KRAS mutant pa-
tients exposed to oxaliplatin plus anti-EGFR antibodies 
 [11, 17] . Although our retrospective evaluation only al-
lows the formation of hypotheses, future studies evaluat-
ing drugs targeting the MAP kinase pathway in patients 
with  KRAS mutant tumors may expect differences with-
in the KRAS codon 12 mutant group.
 Finally, the influence of the three single studies on our 
results cannot be evaluated properly due to the small 
numbers of patients in our subgroups observed in each 
trial.
 In conclusion, this analysis suggests that  KRAS codon 
12 mutations are associated with variable outcomes in pa-
tients with mCRC. This survival variety might be influ-
enced by the chemotherapy combined with cetuximab as 
first-line regimen. Prospective trials will have to clarify 
the sensitivity of  KRAS codon 12 subgroups to chemo-
therapy.
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